Platelet Works as a Point-of-Care Test for ASA Non-Sensitivity

Low-dose aspirin (ASA) is the most common anti-platelet therapy provided to patients with atherosclerotic disease such as peripheral arterial (PAD) and carotid artery stenosis (CAS). However, between 25% 30% of are nonsensitive their therefore at a four-fold higher risk adverse cardiovascular events. In this study, we investigated if Platelet Works, point-of-care platelet function test, could detect ASA patients. We also determined optimal cutoff point (COP) needed diagnose nonsensitivity. To address our objectives, two patient study cohorts were recruited from outpatient clinics tertiary care hospital network. first discovery total 60 recruited. order establish utility Works in detecting sensitivity, simultaneously evaluated each sample light transmission aggregometer (LTA), gold standard for sensitivity testing, addition testing works. nonsensitivity was defined ≥20% maximal aggregation after induction arachidonic acid by LTA. For validation new cohort 40 taking 81 mg These analyzed LTA validate COP study. analysis that 10 therapy. Our data demonstrated had 23.44% ± 5.414% (95% confidence interval [CI] 11.87%-35.02%; P = .0006) response AA when compared sensitive After conducting receiver operating characteristics curve analysis, COPs using chosen based on Youdin Index (YI). When validating acid, noted specificity 91% 69%, respectively. able identify through test good specificity.